



an Open Access Journal by MDPI

## Bioprospecting of Marine and Terrestrial Organisms for New Therapeutics

Guest Editors:

**Dr. Marina Isaeva**

G.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia

**Dr. Elena Leychenko**

Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022 Vladivostok, Russia

Deadline for manuscript submissions:  
**closed (31 August 2023)**

### Message from the Guest Editors

Bioprospecting for biologically active natural products is a well-known tool used in the early stages of drug discovery. The choice of a source for bioprospecting plays an important role in research efforts that is more likely to lead to new drugs. Unique ecosystems unexplored to date such as tundra, desert, salt marshes, and groundwater or mangrove forests are valuable sources of novel products. Advances in high-throughput omics technologies such as proteomics, genomics, and metabolomics have offered wide opportunities for bioprospecting and drug discovery, allowing thousands of molecules to be analyzed simultaneously. Marine ecosystems are an untapped reservoir of biodiversity with enormous potential for bioprospecting of pharmacologically active compounds.

As Guest Editors of the updated Special Issue of *Biomedicines* named "Bioprospecting of Marine and Terrestrial Organisms for New Therapeutics", we would like to invite scientists who deal with marine or terrestrial bioprospecting to make a highly desirable contribution to nature-derived drug discovery.

- bioprospecting
- marine and terrestrial resources
- drug discovery
- natural products



[mdpi.com/si/121667](https://mdpi.com/si/121667)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)